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Phase II studies have suggested that weekly paclitaxel has a higher response rate and better toxicity profile than the conventional
schedule of once every 3 or 4 weeks. Our aim was to evaluate the efficacy of weekly paclitaxel plus cisplatin (PC) vs vinorelbine plus
cisplatin (VC) in chemonaı ¨ve non-small-cell lung cancer (NSCLC) patients. From October 2000 to May 2002, 140 patients were
enrolled. The treatment dose was P 66mgm
 2 intravenous infusion (i.v.) on days 1, 8, and 15, and C 60mgm
 2 i.v. on day 15, or V
23mgm
 2 i.v. on days 1, 8, and 15, and C 60mgm
 2 i.v. on day 15, every 4 weeks. In all, 281 cycles of PC and 307 cycles of VC were
given to the patients in the PC and VC arms, respectively. There were 26 partial responses and one complete response (overall
38.6%) in the PC arm, and no complete responses, but 27 partial responses (overall 38.6%) in the VC arm. Myelosuppression was
more common in the VC arm (Po0.001). Peripheral neuropathy and myalgia were significantly more common in the PC arm
(Po0.001). The median time to disease progression was 6 months in the PC arm and 8.4 months in the VC arm (P¼0.0344). The
median survival time was 11.7 months in the PC arm and 15.4 months in the VC arm (P¼0.297). We concluded that weekly PC is
not suggested for NSCLC patients due to the relatively shorter progression-free survival and more common nonhaematological
toxicities.
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Lung cancer is the most common cancer in Taiwan, and
throughout the world (Parkin et al, 1999). The reported 5-year
survival was 14% in the US and 8% in Europe (Parkin et al, 1999).
The high proportion of disseminated disease and poor prognoses
in these patients has encouraged the decades-long continued
efforts at developing new chemotherapeutic options.
In the past decade, cisplatin in combination with new anticancer
drugs has been found to increase effectively, although modestly,
patient survival in randomised trials and/or meta-analyses, when
compared with cisplatin plus conventional anticancer drugs (Grilli
et al, 1993; Le Chevalier et al, 1994; NSCLC collaborative group,
1995; Bonomi et al, 2000; Baggstrom et al, 2002; Raftopoulos et al,
2002; Schiller et al, 2002; Yana et al, 2002). Among these new
anticancer drugs, vinorelbine was the first drug to show better
survival, when in combination with cisplatin, than conventional
anticancer drugs in combination with cisplatin, in a randomised
phase III study (Le Chevalier et al, 1994). However, which new
anticancer drugs in combination with cisplatin will have the best
efficacy, in terms of longer survival and better toxicity profiles, is
still unknown (Schiller et al, 2002).
In spite of the fact that a phase III randomised trial showed
better survival with paclitaxel plus cisplatin, when comparing
etoposide with cisplatin (Bonomi et al, 2000), many studies have
not demonstrated better survival with paclitaxel plus cisplatin or
carboplatin, when compared with conventional chemotherapy
(Giaccone et al, 1998; Gatzemeier et al, 2000; Raftopoulos et al,
2002). The dosage and schedule of the paclitaxel used varied widely
among the different studies and, thus, probably had different
therapeutic effects on the patients. In contrast to the conventional
paclitaxel treatment schedule of once every 3 or 4 weeks, weekly
paclitaxel treatment was found to have a higher response rate and
better toxicity profiles in phase II trials of both chemonaı ¨ve
patients and patients who had failed previous chemotherapy
(Akerley et al, 1998; Belani, 2001; Chang et al, 2001; Koumakis et al,
2002). However, there has been no report of randomised phase II
or III trials comparing weekly paclitaxel with other new anticancer
drugs. There also has not been a report on the weekly dosage of
paclitaxel that could be safely used with Asian patients, especially
when combining cisplatin treatment. Thus, we conducted a phase
II randomised trial using weekly paclitaxel or vinorelbine plus
cisplatin treatment in inoperable, chemonaı ¨ve non-small-cell lung
cancer (NSCLC) patients to investigate the efficacy of these
regimens.
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Patients
This study was conducted according to existing rules for good
clinical practice, and the protocol was approved by the local ethics
committee. All patients signed informed consent before entry into
the study. Those eligible for entry into the study were patients with
a cytologic or histologic diagnosis of NSCLC; stage IIIb, IV, or
recurrence after surgical treatment; aged 18–80 years; no prior
chemotherapy, immunotherapy, or radiotherapy; a performance
status of 0–2 on the World Health Organization (WHO) scale;
bidimensionally measurable disease; and adequate bone marrow
reserve with a white blood cell count X4000mm
 3, platelets
X100000mm
 3, and hemoglobin X10g/dl. Patients with signs or
symptoms of brain metastases; inadequate liver function (bilirubin
41.5 times and ALT/AST 43 times upper limit normal); or
inadequate renal function with creatinine 42.0mg/dl were
excluded from the study.
Initial work-up included the documentation of the patient’s
history, a physical examination, and a performance score. A
complete blood cell count, urinalysis, serum biochemistry profile,
ECG, chest roentgenography, whole body bone scan, brain CT
scan, and chest CT scan (including liver and adrenal glands) were
also performed.
Study design
Eligible patients were randomised into either the weekly paclitaxel
plus cisplatin regimen (PC arm) or vinorelbine plus cisplatin
regimen (VC arm) by a statistical office not involved in the trial.
Paclitaxel or vinorelbine was given on days 1, 8, and 15 of every 4
weeks. Cisplatin 60mgm
 2 intravenous infusion (i.v.) was given
on day 15. Initially, nine patients from each treatment arm entered
a rapid dose escalation course to determine the weekly dosage of
paclitaxel (escalated from 60 to 66, 72, y mgm
 2) and vinorelbine
(escalated from 20 to 23, 26, y mgm
 2) that would result in the
highest dose intensity. The optimal treatment dose was found to be
paclitaxel 66mgm
 2 i.v. on days 1, 8 and 15 and cisplatin
60mgm
 2 i.v. on day 15, or vinorelbine 23mgm
 2 i.v. on days 1,
8, and 15 and cisplatin 60mgm
 2 i.v. on day 15, every 4 weeks. All
patients in the PC arm received dexamethasone (10mg i.v.),
cimetidine (300mg i.v.), diphenhydramine (50mg i.v.), and
metoclopramide (20mg i.v.) before paclitaxel administration. All
patients in the VC arm received dexamethasone (10mg i.v.) and
metoclopramide (20mg i.v.) before vinorelbine administration. In
addition to the above-mentioned premedications, granisetron and
adequate hydration with half saline was also given on day 15, when
cisplatin treatment was given.
With regard to dose modifications within a cycle, the dose of
paclitaxel or vinorelbine was reduced by 50% if the absolute
neutrophil count (ANC) was from 1.5 to 1.0 10
9l
 1 and/or the
platelet count was 99 to 75 10
9l
 1on the day of the scheduled
chemotherapy. Treatment was omitted if the ANC was less than
1.0 10
9l
 1 or the platelet count was less than 75 10
9l
 1. For
day 15 treatment, CBC was checked every other day after day 15 if
the data on day 15 showed an ANC less than 1.0 10
9l
 1 or a
platelet count less than 75 10
9/l
 1, and treatment was given once
if the ANC was above 1.0 10
9l
 1 and the platelet count was above
75 10
9l
 1 (cisplatin was given at 75% of scheduled dose if the
ANC was 1–1.5 10
9l
 1 and/or the platelet count was 99–
75 10
9l
 1). For dose adjustments in the subsequent cycle, a 25%
reduction in paclitaxel or vinorelbine was instituted when the
patient suffered from grade 4 neutropenia or thrombocytopenia.
Subsequent dose escalation to the original dosage was allowed
providing the patient tolerated the doses given at the 75% level.
For nonhaematological toxicities, paclitaxel or vinorelbine, and
cisplatin were reduced to a 75% dose if there were grade 3
toxicities, and the patient went off-study with grade 4 toxicities,
excluding those due to nausea/vomiting or alopecia. Patients went
off-study if they suffered from grade 3 or worse neuropathy.
After maximal effective chemotherapy (chemotherapy given to a
degree that measurable lesion(s) could not further decrease in
size), radiotherapy was given to all stage IIIb patients, excluding
those with malignant pleural effusion.
Response evaluation
A complete blood cell count was repeated before every injection.
Serum biochemistry was performed before every course of
chemotherapy, and during the course, if clinically indicated. The
Lung Cancer Symptom Scale was recorded before every course of
chemotherapy and when the patient completed or went off the
study (Hollen and Gralla, 1996; Lutz et al, 1997).
Response and study drug-related toxicities were evaluated
according to WHO criteria (World Health Organization, 1979).
Patient responses were reevaluated after every two cycles. In
responding patients and patients with stable disease, a maximum
of six cycles of chemotherapy was given. Those patients whose
tumours progressed were taken off study as soon as this finding
was documented clinically and/or radiographically. All adverse
events, whether thought to be due to chemotherapy or not, were
recorded.
Statistical methodology
This study was designed to enroll 68 qualified patients in each arm.
This calculation assumes that the true response probability for the
best treatment is 10% better than that for the others. Assume that
the smaller treatment response rate was 25% and the higher
treatment response rate was 35%, with a power of 0.9 and a P-value
of 0.05, and that each treatment group requires 68 qualified
patients (Simon et al, 1985).
The response rate and survival were all analysed with an
intention-to-treat principle. The overall survival and time-to-
disease progression were analysed using the Kaplan–Meier
estimation method. Time-to-disease progression was calculated
from the date of initiation of treatment to the date of disease
progression or death. If disease progression had not occurred by
the time of this analysis, progression-free survival was considered
censored at the time of the last follow-up. Survival time was
measured from the date of initiation of treatment to the date of
death. If death had not occurred, survival time was considered
censored at the last follow-up time. All comparisons of clinical
characteristics, response rates, and toxicity incidences were
performed using the ANOVA test. For the statistical analysis of
the Lung Cancer Symptom Scale, the Mann–Whitney test was used
for a comparison of the two arms of treatment, and the Wilcoxon
signed-ranks test was used for comparison before and after
treatment.
RESULTS
Patient characteristics
From October 2000 to May 2002, 140 patients were entered and
randomised into this study, including 70 patients in each arm.
Patient ages ranged from 23 to 80 years, with mean ages of 64.9
years in the PC arm and 64.8 years in the VC arm. The clinical
characteristics of these patients are listed in Table 1. There was no
statistical difference in the clinical characteristics of the two arms
of treatment in terms of sex, age, stage, performance status,
histology, and number of metastases in stage IV patients. All
patients were assessable for toxicity profile and 132 patients were
evaluable for treatment response.
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The 70 patients in the PC arm received a total of 281 cycles of
treatment with a median of four cycles (mean 4.01, range 1–6),
and the 70 patients in the VC arm underwent a total of 307 cycles
of treatment with a median of five cycles (mean 4.39, range 1–6).
The mean percentage of dose administered in the PC arm was
95.3% of the scheduled paclitaxel dose on day 1, 90% on day 8, and
85.2% on day 15, and 88.9% of the scheduled cisplatin dose on day
15. The mean percentage of dose administered in the VC arm was
93.1% of the scheduled vinorelbine dose on day 1, 95.3% on day 8,
and 83.3% on day 15, and 87.6% of the scheduled cisplatin dose on
day 15 (Table 2). Asthenia and myalgia were the major causes of
dose reduction in patients receiving PC treatment. In contrast,
neutropenia accounted for the majority of dose reductions in
patients undergoing VC treatment. Among these 140 patients, 24
were stage IIIb without malignant effusion (15 patients in the PC
arm, nine patients in the VC arm). A total of 14 patients received
radiotherapy after four to six cycles of chemotherapy (eight
patients in the PC arm, six patients in the VC arm), five patients
were not eligible for radiotherapy because of inadequate pulmon-
ary reserve (three patients in the PC arm, two patients in the VC
arm), one patient in the PC arm had early disease progression, and
four patients refused radiotherapy (three patients in the PC arm,
one patient in the VC arm).
Response
After two cycles of treatment, one patient achieved a complete
response and 26 patients achieved a partial response in the PC
arm, and 27 patients achieved a partial response in the VC arm.
Both arms had an overall response rate of 38.6% (95% confidence
interval, 29.3–47.9%, Table 3). In all, 10 of 19 stage IIIb patients in
the PC arm and six of 16 stage IIIb patients in the VC arm had a
partial response to the treatment. The response rate did not
correlate with the patients’ performance status and staging in
either arm.
After a median follow-up time of 18 months, 42 patients in the
PC arm and 38 patients in the VC arm had died. The median time
to disease progression was 6 months in the PC arm, and 8.4
months in the VC arm (Figure 1, P¼0.0344). The median survival
time was 11.7 months in the PC arm (95% confidence interval 7.8–
15.6 months) and 15.4 months in the VC arm (95% confidence
interval 13.9–16.8 months) (P¼0.297, Figure 2). The 1-year
survival rate was 46.3 and 60.9%, respectively (P¼0.12).
Toxicity
All patients enrolled into the study were eligible for toxicity
evaluation. The toxicities were generally mild and reversible,
except for some patients who were left with grade 1 peripheral
neuropathy that lasted for several months. The main toxicities
were haematological (leucopenia and neutropenia) in the VC arm
of treatment (Table 4), and peripheral neuropathy and myalgia in
the PC arm of treatment (Table 5). Febrile neutropenia occurred in
two patients treated with VC, and one of them died in spite of
antibiotics and G-CSF treatment. This patient accounted for the
only toxic death in this study. The incidence of WHO grade 3 or 4
haematological toxicity per patient was: leucopenia 4.3%, neu-
tropenia 10%, anaemia 10%, and thrombocytopenia 1.4% in the PC
Table 1 Patient characteristics
Patient number (%)
Variable
Paclitaxel+
cisplatin
Vinorelbine+
cisplatin P-value
a
Patient number 70 70 0.058
Male 56 46
Female 14 24
Age: mean (range) 64.9 (37–0) 64.8 (23–0) 0.97
WHO performance status
0 13 (18.6) 8 (11.4) 0.412
1 26 (37.1) 29 (41.4)
2 31 (44.3) 33 (47.1)
Stage 19 (27.1) 16 (22.9) 0.54
IIIB
IV 46 (65.7) 48 (68.6)
Recurrence after surgery 5 (7.1) 6 (8.6)
Histology
Adenocarcinoma 46 (65.7) 39 (55.7) 0.407
Squamous cell carcinoma 10 (14.3) 16 (22.9)
NSCLC, type not specified 14 (20) 15 (21.4)
aThere was no statistical difference in patient clinical characteristics between the two
treatment groups.
Table 2 Dose intensity of paclitaxel plus cisplatin treatment vs vinorelbine plus cisplatin treatment
Full dose injections 75% dose injections 50% dose injections Omit or off-study % dose administered
Paclitaxel+cisplatin
a
Paclitaxel Day 1 237 35 9 0 95.3
Day 8 223 32 12 14 90
Day 15 201 36 23 21 85.2
Cisplatin Day 15 231 21 6 23 88.9
Vinorelbine+cisplatin
a
Vinorelbine Day 1 252 25 30 0 93.1
Day 8 272 22 8 0 95.3
Day 15 204 37 48 18 83.3
Cisplatin Day 15 230 38 21 18 87.6
aA total of 281 cycles in the paclitaxel plus cisplatin arm and 307 cycles in the vinorelbine plus cisplatin arm.
Table 3 Overall response rate
Number of Patients (%)
Paclitaxel+cisplatin
(n¼70)
Vinorelbine+cisplatin
(n¼70)
Overall response 27 (38.6) 27 (38.6)
Complete response 1 (1.4) 0
Partial response 26 (37.2) 27 (38.6)
Stable disease 25 (35.7) 32 (45.7)
Progressive disease 14 (20) 7 (10)
Unevaluable 4 (5.7) 4 (5.7)
The 95% confidence interval of the overall response rate was the same in both arms:
29.3–47.9%.
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larm, and leucopenia 28.6%, neutropenia 52.9%, anaemia 14.3%,
and thrombocytopenia 0% in the VC arm. The incidence of grade 3
or 4 leucopenia and neutropenia was significantly higher in the VC
arm (Po0.001). In addition, three patients in the VC arm needed
G-CSF support during their treatment course, while no patient in
the PC arm needed this support. The incidence of WHO grade 2 or
3 peripheral neuropathy per patient was 57.1% in the PC arm and
27.1% in the VC arm (Po0.001). The incidence of WHO grade 2 or
3 myalgia per patient was 32.9% in the PC arm and 5.7% in the VC
arm (Po0.001). Asthenia was noted in both arms, but was more
severe in patients receiving PC treatment. Grades 3–4 asthenia
occurred in 13 patients (18.6%) in the PC arm and in six patients
(8.6%) in the VC arm. Several other mild and tolerable
nonhaematological toxicities were present in both arms (Table 5).
A packed RBC transfusion was needed in 39 patients treated with
PC, with a total of 207 units, and in 40 patients treated with VC,
with a total of 233 units.
Quality of life
In all, 124 patients (62 patients in each arm) completed the
baseline Lung Cancer Symptom Scale questionnaire, and after two
cycles of treatment and/or after going off study. The results of the
completed Lung Cancer Symptom Scale showed that there was no
statistically significant difference in the scales between the PC and
VC arms, either before or two cycles after treatment, or when the
patient went off the study. This held true whether scored by the
patients (nine items) or by the observers (six items), and included
the categories of loss of appetite, fatigue, cough, dyspnea,
haemoptysis, pain, disease severity, daily activity, and quality of
life; however, loss of appetite and pain were worse after two cycles
of treatment in the PC arm (Table 6). When considering all the
treated patients together, there was a slight, although significant
decrease in the scores of all items except haemoptysis (data not
shown).
DISCUSSION
New anticancer drugs in combination with cisplatin usually can
prolong patient survival when compared with cisplatin plus
conventional anticancer drugs (Le Chevalier et al, 1994; Bonomi
et al, 2000; Baggstrom et al, 2002; Raftopoulos et al, 2002; Yana
et al, 2002). However, which new anti-cancer drug is better than
the others is still unknown (Scagliotti et al, 2002; Schiller et al,
2002). Generally, there was no obvious survival difference when
these new anticancer drugs were used in combination with
cisplatin. However, the toxicity profiles could differ among the
new anticancer drugs in combination with cisplatin, due to the
pre-existing different toxicity profiles of the new anticancer drugs,
such as the higher incidence of peripheral neuropathy with
paclitaxel vs the more myelosuppressive effect of vinorelbine
(Scagliotti et al, 2002; Schiller et al, 2002). Furthermore, the
performance and staging statuses of the study population
predicted a major part of the treatment results: the better the
performance status and staging status of the study population, the
better the response rate and the survival, and also the less severe
the treatment toxicities.
Weekly paclitaxel treatment has been found to have a higher
response rate and better toxicity profiles in many phase II studies
of both chemonaı ¨ve patients and patients who have failed previous
chemotherapy (Akerley et al, 1998; Belani, 2001; Chang et al, 2001;
Koumakis et al, 2002). However, there has been no randomised
trial comparing weekly paclitaxel plus cisplatin vs other new
anticancer drugs plus cisplatin. Thus, we performed this phase II
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Figure 1 Time to disease progression of 140 NSCLC patients treated
with cisplatin plus weekly paclitaxel (PC) or vinorelbine (VC). The median
time to disease progression was 6 months in the PC arm, and 8.4 months in
the VC arm (P¼0.0344).
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Figure 2 Survival curve of 140 NSCLC patients treated with cisplatin
plus weekly paclitaxel (PC) or vinorelbine (VC). The median survival time
was 11.7 months in the PC arm and 15.4 months in the VC arm after a
median follow-up time of 18 months (P¼0.297).
Table 4 Haematological toxicity per patient (worst of any course, n¼70 in both arms)
Number of patients (%)
Toxicity\grade Paclitaxel+cisplatin Vinorelbine+cisplatina
012 3 4 01234
Leukopenia
b 37 (52.9) 15 (21.4) 15 (21.4) 3 (4.3) 0 15 (21.4) 16 (22.9) 19 (27.1) 18 (25.7) 2 (2.9)
Neutropenia
b 39 (55.7) 13 (18.6) 11 (15.7) 4 (5.7) 3 (4.3) 13 (18.6) 9 (12.8) 11 (15.7) 24 (34.2) 13 (18.6)
Anaemia 4 (5.7) 20 (28.6) 39 (55.7) 7 (10) 0 2 (2.9) 18 (25.7) 40 (57.1) 9 (12.9) 1 (1.4)
Thrombocytopenia 63 (90) 5 (7.1) 1 (1.4) 1 (1.4) 0 67 (95.7) 2 (2.9) 1 (1.4) 0 0
aFebrile neutropenia occurred in two patients treated with vinorelbine and cisplatin and one patient died in spite of antibiotics and G-CSF treatment.
bANOVA test with P
o0.001.
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lrandomised trial. The weekly dose of paclitaxel single-agent
treatment given to the patient can be 90mgm
 2 or higher (with/
without carboplatin or concomitant radiotherapy) (Belani, 2001;
Chang et al, 2001; Koumakis et al, 2002), even up to
175mgm
 2week
 1 for 6 of 8 weeks (Akerley et al, 1998). However,
there has been no report of a weekly dose of paclitaxel in
combination with cisplatin. The schedule of vinorelbine plus
cisplatin used by Le Chevalier et al in the European trial (Le
Chevalier et al, 1994), with weekly vinorelbine 30mgm
 2 plus
cisplatin 120mgm
 2 on days 1 and 29, and then every 6 weeks, was
too toxic to be tolerable in our patients (Perng et al, 2000). And so,
we initiated a rapid escalation schedule for both paclitaxel and
vinorelbine, with dosages from 60 and 20mgm
 2 i.v. on days 1, 8,
and 15, respectively, while the cisplatin dose was fixed at
60mgm
 2 on day 15 of every 4 weeks. Escalation was performed
with three patients as a cohort and also within every patient’s
cycle. It was found very quickly that a dose intensity of paclitaxel
72mgm
 2 was less than 66mgm
 2 due to frequent dose
reductions, and omitting or delaying on day 15; while the dose
intensity of vinorelbine was 23mgm
 2 higher than 26mgm
 2.
Thus, it was determined to use paclitaxel 66mgm
 2 or vinorelbine
23mgm
 2 on days 1, 8, and 15, plus cisplatin 60mgm
 2 on day 15
of every 4 weeks. The majority of patients tolerated these two
schedules well. For the statistical analysis of treatment efficacy and
toxicities, one may argue that the nine pilot patients from each arm
should not be included in the analysis. However, all these pilot
patients received recommended phase II doses from cycle 2 or 3,
and thus we wanted to include them in the statistical analysis of
this study, with the intention-to-treat principle. Nevertheless, the
overall response rate would be 39.3% in each arm, if we excluded
the nine pilot patients from each arm. The median survival was
changed to 10.8 and 15.8 months in the PC arm and VC arm,
Table 5 Nonhematological toxicity per patient (worst of any course, n¼70 in both arm)
Number of patients (%)
Paclitaxel + cisplatin Vinorelbine + cisplatin
Toxicity\grade 0 1 2 3 4 0 1 2 3 4
Nausea 47 (67.1) 8 (11.4) 15 (21.4) 0 0 42 (60) 15 (21.4) 13 (18.6) 0 0
Vomiting 50 (71.4) 8 (11.4) 11 (15.7) 1 (1.4) 0 53 (75.7) 6 (8.6) 10 (14.3) 1 (1.4) 0
Peripheral neuropathy
a 8 (11.4) 22 (31.4) 37 (52.9) 3 (4.3) 0 21 (30) 30 (42.9) 19 (27.1) 0 0
Asthenia 7 (10) 13 (18.6) 37 (52.9) 13 (18.6) 0 6 (8.6) 11 (15.7) 47 (67.1) 5 (7.1) 1 (1.4)
Myalgia
a 24 (34.3) 23 (32.9) 21 (30) 2 (2.9) 0 45 (64.3) 21 (30) 4 (5.7) 0 0
Alopecia
a 10 (14.3) 33 (47.1) 27 (38.6) 0 0 13 (18.6) 54 (77.1) 3 (4.3) 0 0
aANOVA test with P o0.001. Other toxicities included: six Gr. 1 and two Gr. 2 mucositis, five Gr. 1 constipation, one Gr. 1 and three Gr. 2 pulmonary, one Gr. 3 renal, two Gr. 1
and two Gr. 2 skin rash, one Gr. 2 and one Gr. 3 diarrhoea in paclitaxel + cisplatin arm, four Gr. 1 and four Gr. 2 mucositis, three Gr. 1 pulmonary, one Gr. 1 and one Gr. 2
constipation, one Gr. 2 and one and Gr. 3 diarrhoea, and one hepatitis B reactivation. Gr.¼grade; P¼paclitaxel; C¼cisplatin.
Table 6 Changes in Lung Cancer Symptom Scales in 124 patients who completed the questionnaires
a
PC arm (mean7s.d.) VC arm (mean7s.d.)
Baseline After C2 Off study Baseline After C2 Off study
Appetite loss
Patient 84717 75716 71716 87715 76711 72714
Observer 87720 75721
b 71723 92715 84717 75720
Fatigue
Patient 81717 70714 66715 84715 72712 66714
Observer 84721 73720 66721 88718 79717 68719
Cough
Patient 83716 78715 75715 83714 77714 76717
Observer 89717 85717 82719 87716 82719 78719
Dyspnea
Patient 77715 71713 68712 79714 72712 68712
Observer 82716 75717 72716 84715 79715 73716
Hemoptysis
Patient 96712 96710 96710 99779 8 789 8 78
Observer 96713 97789 8 789 7 713 98779 8 78
Pain
Patient 86719 73717
b 71718 87717 80716 75716
Observer 88721 76720
b 71722
b 90718 86717 81718
Disease severity, patient 80716 71715 67715 79714 73711 70712
Daily activity, patient 77717 69717 66716 79713 73711 68712
Quality of life, patient 79717 69717 68716 79714 73712 70714
aWilcoxon signed-ranks test showed that there was a significant (Po0.001) decrease in the scores of all items, except haemoptysis, when comparing pretreatment scores with
those after two cycles of treatment or after the patient had gone off the study; when all 124 patients were considered together.
bMann–Whitney test showed there was no
difference in the scales between the two arms of treatment either before treatment, two cycles after treatment, or when the patients had gone off the study, except loss of
appetite was more severe in the PC arm after two cycles of treatment (patient, P¼0.021), pain was more severe in the PC arm after two cycles of treatment (patient, P¼0.022;
observer, P¼0.009) and after the patient had gone off the study (observer, P¼0.013).
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lrespectively (P¼0.37); and time to disease progression was 6.1 and
8.8 months, respectively (P¼0.021), after excluding the nine pilot
patients from each arm.
Of course, intrapatient dose escalation for the purpose of
assessing the optimal dosage in each patient is probably not the
best way to conduct a study. Thus, we did not use intrapatient
dose escalation in all the patients. On the other hand, traditional
phase I trials sometimes expose too many patients to subther-
apeutic doses of the drugs and the trials may take a long
time to complete. New trial designs, such as accelerated titration
designs, permitting intrapatient dose escalation and using
fewer patients per dose level, thus, appear to be effective in
reducing the number of patients who are undertreated and
speeding the completion of the phase I trial (Simon et al, 1997).
However, because of the small sample sizes, the optimal
recommended doses generally are determined imprecisely, espe-
cially when allowing intrapatient dose escalation. Thus, a classical
phase I study, followed by a phase II study, probably would be
better than the intrapatient dose escalation in the first nine
patients, as in our study.
It was found from our study that myelosuppression was the
major cause of dose reduction in the VC arm, while severe asthenia
and myalgia caused dose reductions in the PC arm. There was no
obvious interference in the patient’s daily activity if the patient
suffered from neutropenia without infection or fever. However, the
patients felt discomfort when they had asthenia and myalgia. This
kind of discomfort was unpleasant because it occurred ‘weekly’
instead of once every 3 or 4 weeks, which is what usually occurred
when paclitaxel was given once every 3 or 4 weeks. This was
reflected in our patients’ Lung Cancer Symptom Scale as a more
severe loss of appetite in the PC arm after two cycles of treatment.
‘Pain’ was more severe in the PC arm than in the VC arm
throughout the whole treatment course. However, the patients’
reporting of their disease severity, daily activity, and life quality
showed no difference between the two arms before and through the
whole course of treatment (Table 6). Whether it is possible that a
lower dose of paclitaxel plus cisplatin than that used in this study
could have an equal therapeutic effect and similar or lower
toxicities compared to vinorelbine plus cisplatin, is still unknown.
In spite of the fact that patients undergoing VC treatment had a
higher incidence of grade 3 or 4 neutropenia than those receiving
PC treatment, the duration of neutropenia was short and the
recovery quick. Furthermore, vinorelbine is about four times less
expensive than paclitaxel in Taiwan. A study performed by the
Southwest Oncology Group (SWOG) also showed treatment with
paclitaxel plus carboplatin to be substantially and statistically
significantly more expensive than treatment with vinorelbine plus
cisplatin, especially when considering drug cost (Ramsey et al,
2002).
The present study reveals that it is unwise to use weekly
paclitaxel plus cisplatin in patients with NSCLC, at least among our
Asian population, due to the shorter progression-free survival,
relatively more frequent clinic visits, higher drug costs, and higher
frequency of asthenia and myalgia which was not reduced after
changing the paclitaxel schedule from once every 3 or 4 weeks to
once weekly.
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